Skip to main content
Clinical Trials/NCT03016364
NCT03016364UnknownPhase 1

Application Software in Dosage Adjustment for Advanced Cancer Patients With Pain

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 site in 1 country200 target enrollmentStarted: January 1, 2017Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Enrollment
200
Locations
1
Primary Endpoint
Numerical Pain Rating Scale

Study Overview

Brief Summary

The purpose of this trial is to determine whether Application (APP) would help clinical doctors to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets in advanced patients with cancer pain.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •a histologically confirmed diagnosis of Cancer or Sarcoma
  • •advanced patients with severe cancer pain(score >3)
  • •having used or expected to use the Oxycodone Hydrochloride Prolonged-release Tablets

Exclusion Criteria

  • •allergic to Oxycodone Hydrochloride Prolonged-release Tablets, or other reasons (determined by clinical doctors) unable to use the Opioids

Arms & Interventions

APP in dosage adjustment

Experimental

Through the guidance of APP software, clinical doctors try to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain.

Intervention: APP software (Device)

Outcomes

Primary Outcomes

Numerical Pain Rating Scale

Time Frame: upto 8 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Peng Liu

Attending Physician

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Sites (1)

Loading locations...

Similar Trials